This report was first published by Endpoints News. To see the original version, click here
The FDA is launching a pilot program to collect and review clinical trial data in real time, giving scientific reviewers access to the data as it flows in, the agency announced Tuesday.
AstraZeneca and Amgen will be the first companies to participate in the program. The goal is “to shave off months, if not years,” from drug development, FDA AI chief Jeremy Walsh told reporters ahead of the announcement.
您已阅读13%（495字），剩余87%（3252字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。